-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 25, Betta Pharmaceuticals announced that the BPI-361175 tablets declared by the company for the treatment of solid tumors such as advanced non-small cell lung cancer with EGFRC797S mutations and other EGFR-related mutations have been approved by the National Medical Products Administration.
Approved.
BPI-361175 is a new molecular entity with completely independent intellectual property rights independently developed by Betta Pharmaceuticals.
It is a new type of potent and selective fourth representative epidermal growth factor receptor (EGFR) oral Small molecule inhibitors, intended to treat solid tumors such as advanced non-small cell lung cancer with EGFR C797S mutations and other EGFR-related mutations.
On February 25, Betta Pharmaceuticals announced that the BPI-361175 tablets declared by the company for the treatment of solid tumors such as advanced non-small cell lung cancer with EGFRC797S mutations and other EGFR-related mutations have been approved by the National Medical Products Administration.
Approved.
BPI-361175 is a new molecular entity with completely independent intellectual property rights independently developed by Betta Pharmaceuticals.
It is a new type of potent and selective fourth representative epidermal growth factor receptor (EGFR) oral Small molecule inhibitors, intended to treat solid tumors such as advanced non-small cell lung cancer with EGFR C797S mutations and other EGFR-related mutations.
